Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Immucell Corp /de/ ICCC US Equity

Health Care · CIK 811641 · FY ends Dec 31
$9.94
-0.08 (-0.80%)
USD · as of 2026-08-28 · marketstack

Immucell Corp /de/ (Nasdaq: ICCC), an SEC filer in In Vitro & In Vivo Diagnostic Substances, closed at $9.94, -0.8%, on 2026-08-28, with a market cap of $91M as of 2026-08-27, a return on equity of -3.8%, a net margin of -3.8% and 3-year sales growth of 14.2%. Institutional ownership, earnings history and filed financials are on the tabs below.

DateEventWhat happened / filerSource
2026-08-138-K 2.02Results of operations and financial condition (earnings)earnings history (EARN) →sec.gov ↗
2026-07-098-K 2.02Results of operations and financial condition (earnings)earnings history (EARN) →sec.gov ↗
Source: SEC EDGAR (public domain) · history starts 2026-07-09

Every row is a filed document, checked against its EDGAR index.